A single amino acid substitution in a recombinant G protein vaccine drastically curtails protective immunity against respiratory syncytial virus (RSV)

Vaccine

Volumn 21, Issue 19-20, 2003, Pages 2500-2505

  Huang, Yan ^a   Anderson, Robert ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Protective immunity; Recombinant G protein; RSV

Indexed keywords

ALANINE; AMINO ACID; ARGININE; EPITOPE; GUANINE NUCLEOTIDE BINDING PROTEIN; HYBRID PROTEIN; LYSINE; MUTANT PROTEIN; NEUTRALIZING ANTIBODY; PLASMID VECTOR; RECOMBINANT PROTEIN; THIOREDOXIN; VACCINE; VIRUS PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI; IMMUNITY; LOEFFLER PNEUMONIA; LUNG INFILTRATE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROVOCATION TEST; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING; WILD TYPE;

EID: 0038064467     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00044-6     Document Type: Article

References (32)

1. Glezen W.P., Taber L.H., Frank A.L., Kasel J.A. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140:1986;543-546.
2. Holberg C.J., Wright A.L., Martinez F.D.et al. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am. J. Epidemiol. 133:1991;1135-1151.
3. Parrott R.H., Kim H.W., Arrobio J.O.et al. Epidemiology of respiratory syncytial virus infection in Washington, DC. II. Infection and disease with respect to age, immunologic status, race and sex. Am. J. Epidemiol. 98:1973;289-300.
4. Anderson L.J., Parker R.A., Strikas R.L. Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children. J. Infect. Dis. 161:1990;640-646.
5. Navas L, Wang E, De Carvalho V, Robinson J, PICN on infections in Canada. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. J Pediatr 1992;121:348-54.
6. Law BJ, De Carvalho V, PICNIC. Respiratory syncytial virus infections in hospitalized Canadian children: regional differences in patient populations and management practices. Pediatr Infect Dis J 1993;12:659-63.
7. Ruuskanen O., Ogra P.L. Respiratory syncytial virus. Curr. Prob. Pediatr. 23:1993;50-79.
8. Murphy B.R., Prince G.A., Walsh E.E.et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J. Clin. Microbiol. 24:1986;197-202.
9. Kim H.W., Canchola J.G., Brandt C.D.et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:1969;422-433.
10. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., Stewart C.E. An epidemiological study of altered clinical reactivity for respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89:1969;405-421.
11. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M., Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated virus vaccines an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89:1969;435-448.
12. Chin J., Magoffin R.L., Shearer L.A., Schieble J.H., Lennette E.H. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Virology. 1:1969;1-2.
13. Glezen W.P., Paredes A., Allison J.E., Taber L.H., Frank A.L. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J. Pediatr. 98:1981;708-715.
14. Lamprecht C.L., Krause H.E., Mufson M.A. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J. Infect. Dis. 134:1976;211-217.
15. Hemming V.G., Prince G.A., Groothuis J.R., Siber G.R. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin. Microbiol. Rev. 8:1995;22-33.
16. Connors M., Giese N.A., Kulkarni A.B., Firestone C.Y., Morse H.C., Murphy B.R. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 68:1994;5321-5325.
17. Doherty P.C. Vaccines and cytokine-mediated pathology in RSV infection. Trends Microbiol. 2:1994;148-149.
18. Waris M.E., Tsou C., Erdman D.D., Zaki S.R., Anderson L.J. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70:1996;2852-2860.
19. Graham B.S., Henderson G.S., Tang Y.-W., Lu X., Neuzil K.M., Colley D.G. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151:1993;2032-2040.
20. Beasley R., Coleman E.D., Hermon Y., Holst P.E., O'Donnell T.V., Tobias M. Viral respiratory tract infection and exacerbation of asthma in adult patients. Thorax. 43:1988;679-683.
21. Openshaw P.J., Clarke S.L., Record F.M. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int. Immunol. 4:1992;493-500.
22. Kakuk T.J., Soike K., Brideau R.J.et al. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. J. Infect. Dis. 167:1993;553-561.
23. Openshaw P.J.M., O'Donnell D.R. Asthma and the common cold: can viruses imitate worms? Thorax. 49:1994;101-103.
24. Sparer T.E., Matthews S., Hussell T.et al. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J. Exp. Med. 187:1998;1921-1926.
25. Tebbey P.W., Hagen M., Hancock G.E. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J. Exp. Med. 188:1998;1967-1972.
26. Varga S.M., Wissinger E.L., Braciale T.J. The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses. J. Immunol. 165:2000;6487-6495.
27. Mader D., Huang Y., Wang C.et al. Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge. Vaccine. 18:2000;1110-1117.
28. Ryan E.J., Daly L.M., Mills K.H. Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol. 19:2001;293-304.
29. Plotnicky-Gilquin H., Huss T., Aubry J.P.et al. Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment. Virology. 258:1999;128-140.
30. Power U.F., Huss T., Michaud V., Plotnicky-Gilquin H., Bonnefoy J.Y., Nguyen T.N. Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice. J. Virol. 75:2001;12421-12430.
31. Huang Y., Anderson R. Enhanced immune protection by a liposome-encapsulated recombinant respiratory syncytial virus (RSV) vaccine using immunogenic lipids from Deinococcus radiodurans. Vaccine. 20:2002;1586-1592.
32. Bastien N., Trudel M., Simard C. Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines. Vaccine. 17:1999;832-836.